Enlarge / Biogen Inc. headquarters in Cambridge, Massachusetts. Biogen Inc. shares soared after its controversial Alzheimer’s disease therapy was approved by US regulators. (credit: Getty | Bloomberg )
Seniors throughout the US will see a hefty increase to their health care premiums next year thanks in large part to Biogen’s Alzheimer’s drug, Aduhelm, which is priced at $56, 000 per year and is not proven to be clearly effective at treating Alzheimer’s.
The Centers for Medicare & Medicaid Services (CMS) announced Friday that the standard monthly premium for Medicare Part B will rise from $148. 50 in 2021 to $170. 10 within 2022, an increase of $21. 60 or roughly 14. 5 percent. It is the largest increase ever in terms of dollars and among the biggest percentage increases in recent years.
CMS officials said Friday that Aduhelm was responsible for about half of the rise in Part B premiums, according to the Associated Press . Though the particular CMS is still determining how it will cover Aduhelm under Part B, the agency stated the prospect of paying for Aduhelm at all required “additional contingency reserves. ”
Read 9 remaining paragraphs | Comments
